COMPARISON OF OPERATIVE TO MONITORING AND ENDOCRINE THERAPY (COMET) TRIAL FOR LOW RISK DCIS: A PHASE III PROSPECTIVE RANDOMIZED TRIAL Save

Date Added
October 17th, 2017
PRO Number
Pro00065794
Researcher
Nancy Demore

Silhouette
Keywords
Cancer/Breast
Summary

This study looks at the risks and benefits of the "usual approach" (a combination of surgery, radiation and/or hormonal therapy) compared to the close monitoring approach (meaning the condition is watched with follow-up exams and tests such as mammograms, breast ultrasounds, and breast MRI). This study is being conducted because researchers wish to know whether, after 2 years, clinical and quality of life outcomes for women with low risk DCIS who receive usual treatment are the same as those for women with low risk DCIS who receive close monitoring.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clincal-trials@musc.edu

A "Window Trial" On Boswellia, An Extract From Frankincense, For Breast Cancer and Colon Cancer Primary Tumors Save

Date Added
June 20th, 2017
PRO Number
Pro00067127
Researcher
Nancy Demore

Silhouette
Keywords
Cancer/Breast, Cancer/Gastrointestinal
Summary

The overall goal of this study is to see if taking BosPure (boswellia serrata) will change the make up of the tumors of patients who have breast and colon cancer. BosPure is a supplement made from the boswellia serrata plant, which helps to reduce inflammation in the body. BosPure is not approved by the United State Food and Drug Administration (FDA) for the treatment of your disease.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-cto-clinops@musc.edu

Change_preferences

-- OR --

Create_login